SCHEMBL999350

SCHEMBL999350

Nc1ccccc1S(=O)(=O)C(F)(F)F

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.58
CA9 Q16790 4/20 0.56
CA2 P00918 4/20 0.56
CA1 P00915 3/20 0.56
CA12 O43570 2/20 0.56
CA4 P22748 2/20 0.56
CA5A P35218 2/20 0.56
CYP2C9 P11712 1/20 0.56
CA6 P23280 1/20 0.56
CA7 P43166 1/20 0.56
CA14 Q9ULX7 1/20 0.56
CA5B Q9Y2D0 1/20 0.56
HTR6 P50406 1/20 0.50
ALDH1A1 P00352 1/20 0.47
KYNU Q16719 2/20 0.40
GCK P35557 1/20 0.38
TTR P02766 1/20 0.38
CYP3A4 P08684 1/20 0.38
ALOX15 P16050 1/20 0.38
CASP1 P29466 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29800998 1.00 GAA (0.58) GAACA9CA2CA1CA12
SCHEMBL6929900 0.84 CA2 (0.44) GAACA9CA2CA1CA12
SCHEMBL1821664 0.82 ALDH1A1 (0.43) GAACA9CA2CA1CA12
SCHEMBL15544533 0.80 ALDH1A1 (0.42) GAACA9CA2CA1CA12
SCHEMBL5264462 0.80 GAA (0.60) GAACA9CA2CA1CA12
SCHEMBL120713 0.78 CA2 (0.55) CA9CA2CA1CA12CA4
SCHEMBL28416039 0.77 GAA (0.47) GAACA9CA2CA1CA12
SCHEMBL945367 0.76 MEN1 (0.40) GAACA9CA2CA1CA5A
SCHEMBL6264610 0.76 CA2 (0.43) GAACA9CA2CA1CA12
SCHEMBL6000341 0.76 CA2 (0.39) GAACA9CA2CA1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4719391-A2 TRIPLE KINASE INHIBITORS Unogen Biotech Ltd. (US) 2026-04-08 EP disclosed
US-20260085050-A1 TRIPLE KINASE INHIBITORS UNOGEN BIOTECH LTD (US) 2026-03-26 US disclosed
WO-2024249831-A2 TRIPLE KINASE INHIBITORS UNOGEN BIOTECH LTD. (US) 2024-12-05 WO disclosed
US-20240174711-A1 PROCESS FOR PREPARING B-[(7a, 1713)-17-HYDROXY-7-[9-[(4,4,5,5,5-PENTAFLUOROPENTYL)SULFINYL]NONYL]ESTRA-1,3,5(10)-TRIEN-3-YL]-BORONIC ACID INDUSTRIALE CHIMICA S.R.L. (IT) 2024-05-30 US disclosed
WO-2023244996-A2 HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. (US) 2023-12-21 WO disclosed
WO-2023150291-A2 HETEROCYCLIC COMPOUNDS AND METHODS OF USE SCHRÖDINGER, INC. (US) 2023-08-10 WO disclosed
WO-2020222041-A1 METHODS AND COMPOUNDS USING IN-LOOP FLUORINATION CENTRE FOR ADDICTION AND MENTAL HEALTH (CA) 2020-11-05 WO disclosed
EP-3188729-A1 CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS Genzyme Corporation (US) 2017-07-12 EP disclosed
US-20160312006-A1 POLYMER COMPOSITIONS, FILMS, GELS, AND FOAMS CONTAINING SULFONYLIMIDE SALTS, AND ELECTRONIC DEVICES CONTAINING SUCH FILMS, GELS, AND FOAMS RHODIA OPERATIONS (FR) 2016-10-27 US disclosed
WO-2016036796-A1 CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS GENZYME CORPORATION (US) 2016-03-10 WO disclosed
WO-1999032436-A1 INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS BAYER CORPORATION (US) 1999-07-01 WO disclosed
WO-1999032463-A1 INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS BAYER CORPORATION (US) 1999-07-01 WO disclosed
US-5811551-A Palladium catalyzed indolization MERCK & CO., INC. (US) 1998-09-22 US disclosed
US-5811551-A Palladium catalyzed indolization MERCK & CO., INC. (US) 1998-09-22 US disclosed
US-4534788-A CONTROLLING WEEDS IN WHEAT E. I. DU PONT DE NEMOURS AND COMPANY (US) 1985-08-13 US disclosed
EP-0064322-B1 BENZENESULFONYL ISOCYANATES, ISOTHIOCYANATES, CHLORIDES, AND SULFONAMIDES HAVING A FLUORINATED SUBSTITUENT E.I. DU PONT DE NEMOURS AND COMPANY (US) 1985-05-22 EP disclosed
US-4452628-A TRIAZINYL BENZENE SULFONAMIDES E. I. DU PONT DE NEMOURS AND COMPANY (US) 1984-06-05 US disclosed
EP-0023422-B1 HERBICIDAL SULFONAMIDES, PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THEM E.I. DU PONT DE NEMOURS AND COMPANY (US) 1984-02-22 EP disclosed
EP-0064322-A2 Benzenesulfonyl isocyanates, isothiocyanates, chlorides, and sulfonamides having a fluorinated substituent E.I. DU PONT DE NEMOURS AND COMPANY (US) 1982-11-10 EP disclosed
EP-0023422-A2 Herbicidal sulfonamides, preparation and use thereof, and compositions containing them E.I. DU PONT DE NEMOURS AND COMPANY (US) 1981-02-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260085050-A1 TRIPLE KINASE INHIBITORS ALK, ERBB2, ERBB3 GAA 2745/4885CA9 813/4885CA2 875/4885
US-20240174711-A1 PROCESS FOR PREPARING B-[(7a, 1713)-17-HYDROXY-7-[9-[(4,4,5,5,5-PENTAFLUOROPENTYL)SULFINYL]NONYL]ESTRA-1,3,5(10)-TRIEN-3-YL]-BORONIC ACID HSD17B11, CYP19A1, HSD17B7 GAA 3843/4885CA9 1963/4885CA2 3631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.